Fortress Biotech (FBIO) Earnings Analysis

Fortress Biotech (FBIO) next reports earnings on 2026-08-13, consensus EPS -0.2 USD. Last quarter (2026-05-14) it beat with EPS 2.82 USD vs -0.22 USD est (+1381.8%). It has beaten estimates in 2/6 recent quarters (33%). Trailing P/E 0.92.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does FBIO next report earnings?

Next earnings date2026-08-13
Consensus EPS estimate-0.2 USD
Revenue estimate0.02B

FBIO earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-142.82 USD-0.22 USD+1381.8%Beat
2026-03-31-0.21 USD0.42 USD-150%Miss
2025-11-140.11 USD-0.43 USD+125.6%Beat
2025-08-14-0.46 USD-0.31 USD-48.4%Miss
2025-05-21-1.03 USD-0.44 USD-134.1%Miss
2024-11-14-0.76 USD-0.27 USD-181.5%Miss

Beat rate: 2/6 (33%) over reported quarters with consensus data.

FBIO valuation and analyst view

Trailing P/E0.92
Trailing EPS4.051 USD
Price / book0.69
Dividend yield0.00%
Market cap0.12B
Analyst consensusBuy (6 buy / 0 hold / 0 sell)
Avg price target5 USD

Related research pages

Frequently asked questions

When is Fortress Biotech (FBIO)'s next earnings date?

Fortress Biotech is next scheduled to report on 2026-08-13, with a consensus EPS estimate of -0.2 USD and revenue estimate of 0.02B.

Did FBIO beat earnings last quarter?

In its 2026-05-14 report, FBIO posted EPS of 2.82 USD versus a -0.22 USD estimate — a beat of 1381.8%.

What is FBIO's earnings track record?

Over the last 6 reported quarters with consensus data, FBIO beat estimates 2 times (33%).

What is FBIO's current P/E ratio and EPS?

FBIO trades at a trailing P/E of 0.92 on trailing EPS of 4.051033279492667 USD.

What do analysts rate FBIO?

Analyst consensus is "Buy" across 6 ratings (0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 5 USD.